All In Biotech

Drug Trial Radar · NCT05410730

A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

Phase I/II Clinical Study of Dose Escalation and Dose Expansion of SHR-1501 Alone or in Combination With Bacille de Calmette Guerin (BCG) or SHR-1316 in the Treatment of Non-muscle Invasive Bladder Cancer(NMIBC)

Last checked: Nov 19, 2026Latest source record: Jan 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 23, 2022

Primary completion

May 2025

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in combination with BCG or SHR-1316. To evaluate the preliminary efficacy of SHR-1501 alone or in combination with BCG or SHR-1316 in the treatment of NMIBC.

Conditions

  • High-risk NMIBC

Interventions

  • SHR-1501Drug

    SHR-1501 single agent dose escalation, and in combination of BCG or SHR-1316.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicityTime frame: 21 Days
  2. Maximum tolerated doseTime frame: Approximately 2years
  3. Recommended Phase 2 dose (RP2D)Time frame: Approximately 2 years.
  4. CR Rate (cohort 2)Time frame: Approximately 4 years.
  5. 12-month DFS Rate (cohort 1、3、4)Time frame: Approximately 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.